Physician profile
Stephen A Mann
NPI 1558341099
$1,574.85
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,187 · 2020: $282 · 2021: $25.26 · 2023: $16.20 · 2024: $63.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $79.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $79.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $342.94 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $269.88 | 2019-2020 | |
| Glaxosmithkline, LLC. | $226.32 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $140.88 | 2019-2020 | |
| Pfizer INC. | $112.65 | 2019-2020 | |
| Stryker Corporation | $63.56 | 2024 | Insignia |
| E.R. Squibb & Sons, L.L.C. | $54.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $44.36 | 2019 | |
| Abbvie INC. | $43.86 | 2019-2020 | |
| Horizon Therapeutics Plc | $32.37 | 2019 | |
| Astellas Pharma US INC | $30.03 | 2019 | |
| Lilly USA, LLC | $27.19 | 2019 | |
| Nevro Corp. | $25.26 | 2021 | |
| Gilead Sciences, INC. | $19.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.65 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $16.48 | 2019 | |
| Supernus Pharmaceuticals, INC. | $16.20 | 2023 | Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.78 | 2020 | |
| Sanofi Pasteur INC. | $14.65 | 2019 | |
| Daiichi Sankyo INC. | $13.94 | 2019 | |
| Lundbeck LLC | $12.73 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.65 | 2020 | |
| Allergan, INC. | $12.19 | 2019 | |
| Merck Sharp & Dohme LLC | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.